News Articles

U.S. Sen. Tom Carper was recognized Dec. 9 as a Champion for Jobs Creation Through Innovation by the Delaware Chapter of We Work for Health and the Delaware Bioscience Association. Leaders from the biopharmaceutical, science, labor and business sectors gathered at the Delaware Biotechnology Institute in Newark to thank Carper for his leadership. A leading voice in Washington for the biotech industry, Carper was honored for supporting job-creating legislation, including the America Invents Act.

“One of my top priorities as a public servant, beginning with my work as state treasurer, to the U.S. House of Representatives, to governor and now in my role in the U.S. Senate, has been to create a nurturing environment for job creation,” said Carper. “Delaware has become a leader in the biotechnology industry, and I will continue working with my congressional colleagues and the administration to ensure the continued success of this innovative industry in Delaware.”

Speakers included Mark A. Barteau, senior vice provost for research and strategic initiatives at the University of Delaware; J. Michael Bowman, chairman and president of the Delaware Technology Park; Bob Dayton, president of the Delaware Bioscience Association; Dr. Kelvin Lee, director of the Delaware Biotechnology Institute; Katie Macklin, executive director of the Alzheimer’s Association of Delaware; and Dr. Noureddine Melikechi, dean of sciences at Delaware State University.

“We thank Sen. Carper for his steadfast support of the biotechnology sector to foster economic growth through innovation,” said Dayton. “Senator Carper’s understanding of the role innovation plays in creating new opportunities for Delaware businesses and families benefits our state every day.”

Home to some of the world’s largest biotech companies and smallest biotech start-ups, Delaware is an established leader in the biotechnology industry. Carper recently celebrated an important milestone when Incyte won Food and Drug Administration agency approval for a blood cancer drug in November. The senator played a significant role with DuPont, Delaware Economic Development Office and others in the company’s decision to locate in Delaware and has interacted regularly with Incyte over the last 10 years.

"Sen. Tom Carper has been a strong advocate for Incyte in Delaware and in Washington, D.C., and we appreciate his ongoing and generous support," said Paul Friedman, Incyte president and CEO. "Since opening our labs here in Delaware in 2002, Incyte has grown from a small group of dedicated scientists into a biopharmaceutical company with more than 300 employees focused on the discovery, development and now the commercialization of our first FDA-approved product."

The presentation was hosted by We Work for Health Delaware Chapter as part of the quarterly partner meeting, the Delaware Bioscience Association and the Delaware Biotechnology Institute.

We Work For Health Delaware Chapter is a grassroots initiative that unites health consumers, biopharmaceutical company employees and retirees, vendors, suppliers and other business, academic and community partners to demonstrate how these diverse groups work together to improve America’s healthcare system and strengthen its economy. Connect with them on Facebook and Twitter.

Full story: